Abstract: Portal hypertension, as one of the major complications of liver cirrhosis, is a common clinical syndrome
characterized by an increased portal pressure and the formation of portal-systemic collaterals. Currently no ideal therapeutic
agent has been available for portal hypertension. Sorafenib is an oral tyrosine kinase inhibitor that has been shown to
significantly improve blood flow dynamics, inhibit angiogenesis, reduce liver fibrosis and decrease portal pressure in the
treatment of portal hypertension. The authors review the progress in the research of sorafenib in the treatment of portal
hypertesion and the mechanisms of its actions.